U.S. patent application number 14/536080 was filed with the patent office on 2015-05-07 for inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity.
This patent application is currently assigned to INSERM (Institut National de la Sante et de la Recherche Medicale). The applicant listed for this patent is Philippe Pierre. Invention is credited to Philippe Pierre.
Application Number | 20150126549 14/536080 |
Document ID | / |
Family ID | 41571430 |
Filed Date | 2015-05-07 |
United States Patent
Application |
20150126549 |
Kind Code |
A1 |
Pierre; Philippe |
May 7, 2015 |
Inhibitors of the PP1/GADD34 Complex for the Treatment of a
Condition Requiring an Immunosuppressive Activity
Abstract
The present invention relates to the general field of the
treatment and prevention of diseases involving an inflammatory
condition, namely sepsis or infectious or viral diseases as well as
diseases requiring for the of treatment an immunosuppressive
activity namely autoimmune diseases and graft rejection. In
particular, the invention relates to an inhibitor of the activity
or the formation of the PP1/GADD34 complex for the treatment of a
condition requiring an immunosuppressive activity or an
anti-inflammatory activity.
Inventors: |
Pierre; Philippe; (Cedex 09
Marseille, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Pierre; Philippe |
Cedex 09 Marseille |
|
FR |
|
|
Assignee: |
INSERM (Institut National de la
Sante et de la Recherche Medicale)
Paris
FR
Universite d'Aix-Marseille
Marseille
FR
|
Family ID: |
41571430 |
Appl. No.: |
14/536080 |
Filed: |
November 7, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13511151 |
Jun 18, 2012 |
|
|
|
PCT/EP2010/067975 |
Nov 23, 2010 |
|
|
|
14536080 |
|
|
|
|
Current U.S.
Class: |
514/311 ;
514/451 |
Current CPC
Class: |
A61P 37/06 20180101;
A61P 29/00 20180101; A61P 31/12 20180101; A61P 37/08 20180101; A61P
37/00 20180101; A61K 31/00 20130101; A61K 31/35 20130101; A61K
31/47 20130101; A61P 17/00 20180101; A61P 19/02 20180101; A61P
19/04 20180101; A61P 31/22 20180101; Y02A 50/30 20180101; A61P
31/00 20180101; A61P 35/00 20180101; A61P 17/06 20180101; A61P
31/16 20180101; A61P 11/00 20180101 |
Class at
Publication: |
514/311 ;
514/451 |
International
Class: |
A61K 31/47 20060101
A61K031/47; A61K 31/35 20060101 A61K031/35 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 23, 2009 |
EP |
09306124.0 |
Claims
1-15. (canceled)
16. A method of treating inflammatory bowel disease in a patient in
need thereof, comprising the step of administering to said patient
a therapeutic amount of an inhibitor of activity or formation of a
PP1/GADD34 complex.
17. The method of claim 16, wherein said inhibitor is an inhibitor
of GADD34.
18. The method of claim 16, wherein said inhibitor is an inhibitor
of PP1 in complex with GADD34.
19. The method of claim 16, wherein said inhibitor inhibits an
interaction domain comprising amino acid residues 540 to 600 of
GADD34.
20. The method of claim 16, wherein said inhibitor is selected from
the groups consisting of salubrinal, tautomycine, calyculin A, a
peptide comprising a fragment of GADD34 and a peptide consisting of
a fragment of GADD34.
21. The method of claim 16, wherein said inhibitor is a selective
inhibitor of said PP1/GADD34 complex.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to the general field of the
treatment and prevention of diseases involving an inflammatory
condition, namely sepsis or infectious or viral diseases as well as
diseases requiring for the of treatment an immunosuppressive
activity namely autoimmune diseases and graft rejection.
BACKGROUND OF THE INVENTION
[0002] Dendritic cells (DCs) are regulators of the immune response
whose antigen processing activities are controlled in response to
pathogen-associated molecular patterns (PAMPS). DCs are most
efficient at initiating antigen-specific responses, inducing
differentiation of naive T cells. Upon stimulation via pattern
recognition receptors, DCs begin a maturation process characterized
by functional changes, such as cytokine production (e.g. IL-12) or
upregulation of antigen presentation [Mellman, I. et al., 2001].
Double-stranded RNA (ds-RNA) present as viral genome or in virally
infected cells is recognized by Toll-like receptor 3 (TLR3), which
is expressed by several specialized cell types including DCs
[Alexopoulou, L., et Al., 2001]. Upon stimulation with poly I:C, a
dsRNA mimic, TLR3 triggers a complex signaling cascade leading to
type I interferons (IFN) production [Alexopoulou, L., et Al., 2001
and Kawai, T. et Al., 2006]. In addition to membrane bound TLR3,
another intracellular dsRNA receptor, the RNA helicase melanoma
associated gene-5 (MDA5) induces type I IFN production in response
to poly I:C via a different signaling cascade also leading to the
nuclear translocation of IRF-3 and IRF-7 [Kawai, T. et Al., 2006
and Gitlin, L. et Al., 2006]. Once bound to their receptor on the
cell surface, type I interferons activate the Janus tyrosine
kinase/signal transducer and activator pathway, which induces the
expression of a wide spectrum of cellular genes. Among these, there
is the double-stranded RNA-dependent protein kinase (PKR), a key
player of the interferon-mediated antiviral action, which is
involved in cell differentiation and apoptosis [Donze, O. et al.,
2004 and Scheuner, D. et al., 2006].
[0003] PKR is also activated by dsRNA in the cytosol and triggers
translation initiation factor 2-alpha phosphorylation on serine 51
(eIF2-.alpha.) [Proud, C. G, 1995 and Williams, B. R., 1999]
leading to protein synthesis shut-off and inhibition of viral
replication. In addition to dsRNA detection, different stress
signals trigger eIF2-.alpha.phosphorylation, thus attenuating mRNA
translation and activating gene expression programs known globally
as the integrated stress response (ISR) [Harding, H. P. et al.,
2003]. To date, four kinases have been identified to mediate ISR:
PKR, PERK (protein kinase RNA (PKR)-like ER kinase) [Harding, H.
P., et al., 2000], GCN2 (general control non-derepressible-2)
[Zhang, P. et al. 2002 and Berlanga, J. J. et al. 2006] and HRI
(heme-regulated inhibitor) [Chen, J. J. et al., 1995 and Lu, L., et
Al., 2001]. ER stress-mediated eIF2-.alpha. phosphorylation is
carried out by PERK, which is activated by an excess of unfolded
proteins accumulating in the ER lumen [Harding, H. P., et al.,
2000]. Activated PERK phosphorylates eIF2-.alpha., attenuating
protein synthesis and triggering the translation of specific
molecules such as the transcription factor ATF4, which is necessary
to mount part of a particular ISR, known as the unfolded protein
response (UPR) [Ron, D. & Walter, P., 2007 and Todd, D. J., et
Al., 2008 and Zhang, K. & Kaufman, R. J. et Al., 2008].
[0004] Interestingly, dsRNA detection by TLR3, MDA5 and PKR is
likely to occur concomitantly in cells like DCs, thus potentially
resulting in conflicting signaling events and opposite biological
effects (e.g. cellular activation v.s. translational arrest and/or
anergy).
[0005] The inventors demonstrate here that poly I:C detection by
DCs or fibroblasts activates the negative feedback control loop of
the UPR and induces eIF2-.alpha. dephosphorylation through
phosphatase 1 (PP1) and the expression of its inducible cofactor,
the growth arrest and DNA damage-inducible protein 34
(GADD34/MyD116) [Connor, J. H., et Al., 2001]. As a consequence,
the translational arrest, normally mediated through eIF2-.alpha.
phosphorylation in response to cytosolic dsRNA detection,
tapsigargin or tryptophan starvation, is prevented in activated
DCs. This phenomenon allows DCs to perform their immune function,
in conditions under which translation arrest would normally impair
their activity. This point is illustrated by the demonstration that
the absence of stress-induced translational inhibition in activated
DCs is essential to produce normal amounts of interferon-.beta. and
to prevent caspase-3 cleavage and apoptosis and that DCs
inactivated for the GADD34 gene are incapable of producing
cytokines.
[0006] As known, DCs play major role in inflammatory condition like
autoimmune diseases by releasing inflammatory cytokines like
interferon-.beta. or IL-12. So, inhibit GADD34 could allow
controlling the overactive immune response in pathogenic condition
like autoimmune diseases or graft rejection by blocking the release
of inflammatory cytokines release by DCs or other cells.
[0007] As of today, very few treatments are available for the
treatment of autoimmune diseases or graft rejection, that have an
acceptable safety index.
[0008] Thus, there is a permanent need in the art for new molecules
for the treatment of autoimmune diseases or graft rejection.
SUMMARY OF THE INVENTION
[0009] The invention is based on the discovery that GADD34
represents a novel and promising target controlling inflammation by
blocking the release of inflammatory cytokines and other secreted
molecular mediators leading to pathogenic conditions such as
autoimmune diseases or infectious and non-infectious diseases
leading to hypercytokinemia including graft versus host disease
(GVHD), acute respiratory distress syndrome (ARDS), sepsis, avian
influenza, smallpox, and systemic inflammatory response syndrome
(SIRS). Inhibitors of GADD34 are already known for the treatment of
cancer like carcinoma or sarcoma (see for example WO
2008028965).
[0010] Thus, the invention relates to an inhibitor of the activity
or the formation of the PP1/GADD34 complex for the treatment of a
condition requiring an immunosuppressive activity or an
anti-inflammatory activity.
[0011] In one aspect, the invention relates to an inhibitor
according to the invention for the treatment of autoimmune diseases
or inflammatory conditions.
[0012] In a second aspect, the invention relates to an inhibitor
according to the invention for the treatment of graft
rejection.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0013] As used herein, the term "dendritic cells (DCs)" denotes
immune cells that form part of the mammalian immune system. Their
main function is to process antigen material and present it on the
surface to other cells of the immune system, thus functioning as
antigen-presenting cells.
[0014] As used herein, the term "autoimmune diseases" denotes an
overactive immune response of the body against substances and
tissues normally present in the body. In other words, the body
really attacks its own cells. This may be restricted to certain
organs (e.g. in thyroiditis) or involve a particular tissue in
different places (e.g. Goodpasture's disease which may affect the
basement membrane in both the lung and the kidney). The treatment
of autoimmune diseases is typically with
immunosuppression--medication which decreases the immune
response.
[0015] As used herein, the term "Poly I:C"
(polyinosinic:polycytidylic acid or polyinosinic-polycytidylic acid
sodium salt) denotes an immunostimulant. It is used to simulate
viral infections. Poly I:C is known to interact with toll-like
receptor (TLR) 3, which is expressed in the intracellular
compartments of B-cells and dendritic cells. Poly I:C is
structurally similar to double-stranded RNA, which is present in
some viruses and is a "natural" stimulant of TLR3. Thus, Poly I:C
can be considered a synthetic analog of double-stranded RNA and is
a common tool for scientific research on the immune system.
[0016] As used herein, the term "GADD34" for "DNA damage-inducible
protein 34" or MyD116 denotes a protein inhibitor 1 (I-1)
interacting protein that associates with the C terminus of human
I-1. GADD34, whose expression in mammalian cells is elevated by
growth arrest, DNA damage, and other forms of cell stress, has
structural homology to a region of the herpes simplex virus (HSV-1)
neurovirulence factor ICP-345, previously shown to bind PP1. An
exemplary sequence for human GADD34 gene (PPP1R15A) is deposited in
the database NCBI under accession number NW.sub.--927240.1 and mRNA
U83981.1.
[0017] As used herein, the term "an inhibitor of the formation of
the PP1/GADD34 complex" denotes an inhibitor able to compete in the
.mu.M range with GADD34 to form a complex with PP1 and thereby
render said complex non functional, or to block GADD34 expression
or to render GADD34 structurally inactive. In another term, "an
inhibitor of the formation of the PP1/GADD34 complex" will have an
EC.sub.50 not greater than 50 .mu.M and preferably not greater than
25 .mu.M.
[0018] As used herein, the term "an inhibitor of the activity of
the PP1/GADD34 complex" denotes an inhibitor in the .mu.M range
that is responsible for the non expression of said complex in the
cell and/or for the non induction of a reaction of the immune
system or for a decreased reaction of the immune system compared
with its reaction in the absence of said inhibitor. In another
term, "an inhibitor of the activity of the PP1/GADD34 complex" will
have an EC50 not greater than 50 .mu.M and preferably not greater
than 25 .mu.M.
[0019] As used herein, the term `selective inhibitor" denotes a
compound which just inhibit GADD34 activity or expression, without
affecting the activity of the non inducible PP1 activator CReP or
PP1 activity outside of the GADD34 complex.
[0020] As used herein, the term "protein phosphatase 1 (PP1)"
denotes a major eukaryotic protein serine/threonine phosphatase
that regulates an enormous variety of cellular functions through
the interaction of its catalytic subunit (PP1c) with over fifty
different established or putative regulatory subunits.
[0021] As used herein, the term "graft" denotes a cell, tissue,
organ or otherwise any biological compatible lattice for
transplantation.
[0022] As used herein, the term "graft rejection" denotes acute or
chronic rejection of cells, tissue or solid organ allo- or
xenografts of e.g. pancreatic islets, stem cells, bone marrow,
skin, muscle, corneal tissue, neuronal tissue, heart, lung,
combined heart-lung, kidney, liver, bowel, pancreas, trachea or
oesophagus, or graft-versus-host diseases.
[0023] As used herein, the term "allogeneic" denotes a graft
derived from a different animal of the same species.
[0024] As used herein, the term "xenogeneic" denotes a graft
derived from an animal of a different species.
[0025] As used herein, the term "transplant" denotes a
biocompatible lattice or a donor tissue, organ or cell, to be
transplanted. An example of a transplant may include but is not
limited to skin, bone marrow, and solid organs such as heart,
pancreas, kidney, lung and liver.
[0026] As used herein, the terms "treating" or "treatment", denotes
reversing, alleviating, inhibiting the progress of, or preventing
the disorder or condition to which such term applies, or one or
more symptoms of such a disorder or condition.
Inhibitors and Uses Thereof
[0027] A first aspect of the invention relates to an inhibitor of
the activity or the formation of the PP1/GADD34 complex for the
treatment of a condition requiring an immunosuppressive activity or
an anti-inflammatory activity.
[0028] In a first embodiment the inhibitor according to the
invention is useful for the treatment of autoimmune diseases.
[0029] The inhibitor may be useful for the treatment of autoimmune
diseases including, but not limited to systemic lupus
erythematosus, arthritis, Sjogren's syndrome, psoriasis, dermatitis
herpetiformis, vitiligo, mycosis fungoides, allergic contact
dermatitis, atopic dermatitis, lichen planus, Pityriasis
lichenoides and varioliforms acuta (PLEVA), catastrophic
antiphospholipid syndrome.
[0030] In a second embodiment, the inhibitor according to the
invention is useful for the treatment of inflammatory
conditions.
[0031] As used herein, the term "inflammatory condition(s)" denotes
a biological response characterized by cellular and biochemical
components. For example, the cellular component is characterized by
leukocyte migration (swelling) and the biochemical component is
characterized by activation of the complement system or by the
production of mediator, chemokines and cytokines.
[0032] The inhibitor may be useful for the treatment of
inflammatory conditions including, but not limited to allergy,
asthma, Myopathies, cancer, acute respiratory distress syndrome
(ARDS), sepsis, and systemic inflammatory response syndrome (SIRS),
Inflamatory bowel diseases, psoriasis.
[0033] In another preferred embodiment, the inflammatory condition
is sepsis.
[0034] In another embodiment, the inhibitor according to the
invention may be useful for the treatment of inflammatory
conditions caused by an infectious or viral disease or any disease
leading to aggravated conditions due to an hyper production of
inflammatory mediators or cytokines storms.
[0035] In a preferred embodiment, inflammatory conditions caused by
an infectious or viral disease may be Chikungunya virus infection,
influenza infection, herpes infection avian influenza, Smallpox,
severe acute respiratory syndrome (SARS).
[0036] In a most preferred embodiment, the viral disease is caused
by a Chikungunya virus infection.
[0037] In a third embodiment, the inhibitor according to the
invention is useful for the treatment of graft rejection or graft
versus host disease (GVHD).
[0038] In a preferred embodiment, the graft rejection concerns an
allogeneic or a xenogeneic transplant.
[0039] In another preferred embodiment, the inhibitor according to
the invention is an inhibitor of GADD34.
[0040] In another preferred embodiment, the inhibitor according to
the invention is an inhibitor of PP1 in complex with GADD34.
[0041] In another preferred embodiment, the inhibitor according to
the invention inhibits the interaction domain comprised between
amino acids residues 540 and 600 of GADD34.
[0042] In a preferred embodiment, the inhibitor according to the
invention is selected from salubrinal, tautomycine and calyculin
A.
[0043] In another preferred embodiment, the inhibitor according to
the invention is a peptide consisting of or comprising a fragment
of GADD34.
[0044] In another embodiment, the inhibitor according to the
invention is a selective inhibitor of GADD34. A selective inhibitor
according to the invention may be found in the patent application
W02008028965.
[0045] In a preferred embodiment, the selective inhibitor is
selected from small inactivating RNAs or other compounds capable of
blocking the expression of GADD34 at the transcription or
translational level.
[0046] In one embodiment, inhibitor of the invention may be a low
molecular weight inhibitor, e. g. a small organic molecule (natural
or not).
[0047] The term "small organic molecule" refers to a molecule
(natural or not) of a size comparable to those organic molecules
generally used in pharmaceuticals. The term excludes biological
macromolecules (e. g., proteins, nucleic acids, etc.). Preferred
small organic molecules range in size up to about 5000 Da, more
preferably up to 2000 Da, and most preferably up to about 1000
Da.
[0048] In another embodiment, inhibitor of the invention may
consist in an antibody which inhibits the activity or the formation
of the PP1/GADD34 complex or an antibody fragment which inhibits
the activity or the formation of the PP1/GADD34 complex.
[0049] Antibodies directed against the PP1/GADD34 complex can be
raised according to known methods by administering the appropriate
antigen or epitope to a host animal selected, e.g., from pigs,
cows, horses, rabbits, goats, sheep, and mice, among others.
Various adjuvants known in the art can be used to enhance antibody
production. Although antibodies useful in practicing the invention
can be polyclonal, monoclonal antibodies are preferred. Monoclonal
antibodies against the PP1/GADD34 complex can be prepared and
isolated using any technique that provides for the production of
antibody molecules by continuous cell lines in culture. Techniques
for production and isolation include but are not limited to the
hybridoma technique originally described by Kohler and Milstein
(1975); the human B-cell hybridoma technique (Cote et al., 1983);
and the EBV-hybridoma technique (Cole et al. 1985). Alternatively,
techniques described for the production of single chain antibodies
(see, e.g., U.S. Pat. No. 4,946,778) can be adapted to produce
anti-GADD34/PP1 complex single chain antibodies. PP1/GADD34 complex
inhibitor useful in practicing the present invention also include
anti-PP1/GADD34 complex antibody fragments including but not
limited to F(ab').sub.2 fragments, which can be generated by pepsin
digestion of an intact antibody molecule, and Fab fragments, which
can be generated by reducing the disulfide bridges of the
F(ab').sub.2 fragments. Alternatively, Fab and/or scFv expression
libraries can be constructed to allow rapid identification of
fragments having the desired specificity to the PP1/GADD34
complex.
[0050] Humanized anti-PP1/GADD34 complex antibodies and antibody
fragments thereof may also be prepared according to known
techniques. "Humanized antibodies" are forms of non-human (e.g.,
rodent) chimeric antibodies that contain minimal sequence derived
from non-human immunoglobulin. For the most part, humanized
antibodies are human immunoglobulins (recipient antibody) in which
residues from a hypervariable region (CDRs) of the recipient are
replaced by residues from a hypervariable region of a non-human
species (donor antibody) such as mouse, rat, rabbit or nonhuman
primate having the desired specificity, affinity and capacity. In
some instances, framework region (FR) residues of the human
immunoglobulin are replaced by corresponding non-human residues.
Furthermore, humanized antibodies may comprise residues that are
not found in the recipient antibody or in the donor antibody. These
modifications are made to further refine antibody performance. In
general, the humanized antibody will comprise substantially all of
at least one, and typically two, variable domains, in which all or
substantially all of the hypervariable loops correspond to those of
a non-human immunoglobulin and all or substantially all of the FRs
are those of a human immunoglobulin sequence. The humanized
antibody optionally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin. Methods for making humanized antibodies are
described, for example, by Winter (U.S. Pat. No. 5,225,539) and
Boss (Celltech, U.S. Pat. No. 4,816,397).
[0051] In still another embodiment, PP1/GADD34 complex inhibitor
may be selected from aptamers. Aptamers are a class of molecule
that represents an alternative to antibodies in term of molecular
recognition. Aptamers are oligonucleotide or oligopeptide sequences
with the capacity to recognize virtually any class of target
molecules with high affinity and specificity. Such ligands may be
isolated through Systematic Evolution of Ligands by EXponential
enrichment (SELEX) of a random sequence library, as described in
Tuerk C. and Gold L., 1990. The random sequence library is
obtainable by combinatorial chemical synthesis of DNA. In this
library, each member is a linear oligomer, eventually chemically
modified, of a unique sequence. Possible modifications, uses and
advantages of this class of molecules have been reviewed in
Jayasena S. D., 1999. Peptide aptamers consists of a
conformationally constrained antibody variable region displayed by
a platform protein, such as E. coli Thioredoxin A that are selected
from combinatorial libraries by two hybrid methods (Colas et al.,
1996).
Therapeutic Composition
[0052] Another object of the invention relates to a therapeutic
composition comprising an inhibitor according to the invention for
the treatment of a condition requiring an immunosuppressive
activity.
[0053] Any therapeutic agent of the invention may be combined with
pharmaceutically acceptable excipients, and optionally
sustained-release matrices, such as biodegradable polymers, to form
therapeutic compositions.
[0054] "Pharmaceutically" or "pharmaceutically acceptable" refers
to molecular entities and compositions that do not produce an
adverse, allergic or other untoward reaction when administered to a
mammal, especially a human, as appropriate. A pharmaceutically
acceptable carrier or excipient refers to a non-toxic solid,
semi-solid or liquid filler, diluent, encapsulating material or
formulation auxiliary of any type.
[0055] The form of the pharmaceutical compositions, the route of
administration, the dosage and the regimen naturally depend upon
the condition to be treated, the severity of the illness, the age,
weight, and sex of the patient, etc.
[0056] The pharmaceutical compositions of the invention can be
formulated for a topical, oral, intranasal, parenteral,
intraocular, intravenous, intramuscular or subcutaneous
administration and the like.
[0057] Preferably, the pharmaceutical compositions contain vehicles
which are pharmaceutically acceptable for a formulation capable of
being injected. These may be in particular isotonic, sterile,
saline solutions (monosodium or disodium phosphate, sodium,
potassium, calcium or magnesium chloride and the like or mixtures
of such salts), or dry, especially freeze-dried compositions which
upon addition, depending on the case, of sterilized water or
physiological saline, permit the constitution of injectable
solutions.
[0058] The doses used for the administration can be adapted as a
function of various parameters, and in particular as a function of
the mode of administration used, of the relevant pathology, or
alternatively of the desired duration of treatment.
[0059] In addition, other pharmaceutically acceptable forms
include, e.g. tablets or other solids for oral administration; time
release capsules; and any other form currently can be used.
[0060] Alternatively, compounds of the invention which inhibit the
activity or the formation of the PP1/GADD34 complex can be further
identified by screening methods as hereinafter described.
Screening Methods
[0061] Another object of the invention relates to a method for
screening a compound which inhibits the activity or the formation
of the PP1/GADD34 complex.
[0062] In particular, the invention provides a method for screening
an inhibitor of the PP1/GADD34 complex for the treatment of
different disorder.
[0063] For example, the screening method may measure the binding of
a candidate compound to PP1/GADD34 complex, or to cells or
membranes bearing PP1/GADD34 complex or a fusion protein thereof by
means of a label directly or indirectly associated with the
candidate compound. Alternatively, a screening method may involve
measuring or, qualitatively or quantitatively, detecting the
competition of binding of a candidate compound to the receptor with
a labelled competitor (e.g., antagonist).
[0064] In a particular embodiment, the screening method of the
invention comprises the step consisting of:
[0065] a) providing a plurality of cells expressing the PP1/GADD34
complex:
[0066] b) incubating said cells with a candidate compound;
[0067] c) determining whether said candidate compound binds to
PP1/GADD34 complex; and
[0068] d) selecting the candidate compound that inhibits the
PP1/GADD34 complex.
[0069] A test for screening inhibitors according to the invention
can be found in Boyce, M. et al., 2005 and Novoa, I. et al.,
2001.
[0070] Several methods can be use to screen for such inhibitor:
[0071] 1: In vitro using eIF-2 phosphorylation detection with
specific antibodies (WB or ELISA) in rabbit reticulocyte lysate.
[0072] 2: A screening method using recombinant GADD34 and PP1
followed by size exclusion chromatography to follow the disruption
of the complex in presence of potential inhibitors. [0073] 3: A
functional assay in which cytokine production is monitored in
activated DCs upon exposure to the inhibitor. Intracellular FACS
scan or ELISA can be used to detect cytokine production in
multiwell plates. [0074] 4: Rapid and complete translational arrest
in response to tunicamycin in presence of potential inhibitors.
Detection of translation can be performed by FACS using the SUnSET
technology (Schmidt et al. Nature Methods 2009).
[0075] In general, such screening methods involve providing
appropriate cells which express the PP1/GADD34 complex, its
orthologs and derivatives thereof on their surface. In particular,
a nucleic acid encoding the PP1/GADD34 complex may be employed to
transfect cells to thereby express the PP1/GADD34 complex. Such a
transfection may be achieved by methods well known in the art.
[0076] In a particular embodiment, cells are selected from the
group consisting dendritic cells (DCs) and other immune cells
involved in cytokine and inflammatory mediator release including
but not limited to macrophages, T cells, neutrophiles,
mastocytes.
[0077] The screening method of the invention may be employed for
determining an inhibitor by contacting such cells with compounds to
be screened and determining whether such compound inhibit or not
the PP1/GADD34 complex.
[0078] According to a one embodiment of the invention, the
candidate compound may be selected from a library of compounds
previously synthesised, or a library of compounds for which the
structure is determined in a database, or from a library of
compounds that have been synthesised de novo or natural
compounds.
[0079] The candidate compound may be selected from the group of (a)
proteins or peptides, (b) nucleic acids and (c) organic or chemical
compounds (natural or not). Illustratively, libraries of
pre-selected candidate nucleic acids may be obtained by performing
the SELEX method as described in documents U.S. Pat. No. 5,475,096
and U.S. Pat. No. 5,270,163. Further illustratively, the candidate
compound may be selected from the group of antibodies directed
against the PP1/GADD34 complex.
[0080] Such the method may be used to screen PP1/GADD34 complex
inhibitor according to the invention.
[0081] The invention will be further illustrated by the following
figures and examples. However, these examples and figures should
not be interpreted in any way as limiting the scope of the present
invention.
FIGURES
[0082] FIGS. 1A-1E. Transcription factors ATF4 and CHOP are induced
in DCs upon poly I:C stimulation. FIG. 1A ATF4 mRNA expression was
measured by quantitative PCR (qPCR) in response to poly I:C
stimulation at different time points (left panel). ATF4 protein
levels were quantified in nuclear extract of poly I:C-stimulated
DCs by immunoblot. Protein levels were increased after 8 h of
stimulation, similarly to cells treated with tunicamycin. (right
panel). Mock was treated with DMSO, in which tunicamycin was
dissolved; immunoblot for histone H1 is shown as equal loading
control. FIG. 1B CHOP mRNA expression was found by qPCR to be
increased by 8 folds in poly I:C-activated DCs. FIG. 1C Phosphatase
1 (PP1) mRNA expression levels were only modestly increased by poly
I:C. FIG. 1D GADD34 mRNA expression was increased up to 14 folds
(top panel). A treatment with the proteasome inhibitor MG132 (2
.mu.M, added 4 h before harvesting) was necessary to allow GADD34
detection by immunoblot. GADD34 accumulates in the cells after 8 h
of poly I:C stimulation, in comparable amounts to those induced by
tunicamycin. FIG. 1E CReP (constitutive PP1 cofactor) mRNA
expression levels were very modestly induced.
[0083] FIGS. 2A-2D. Protein synthesis and eIF2-.alpha.
dephosphorylation are tightly regulated during poly I:C induced DC
maturation. FIG. 2A Protein synthesis was quantified in poly I:C
activated DCs using puromycin labelling followed by immunoblot with
the anti-puromycin mAb 12D10. Protein synthesis was enhanced in the
first hours of poly I:C stimulation, followed by a reduction after
8 h. Controls are cells non treated with puromycin (co) and cells
treated with cycloheximide (chx) 5' min before puromycin
incorporation. .beta.-actin immunoblot is shown for equal loading
control. FIG. 2B Immunoblot for phosphorylated (P-eIF2-.alpha.) and
total eIF2-.alpha. were performed on the same DC extracts.
Quantification of P-eIF2-.alpha. levels is also shown. FIG. 2C DCs
were activated with soluble poly I:C for 24 h and treated with 75
.mu.M salubrinal (specific inhibitor of the PP1-GADD34 complex) for
the last 4 h of stimulation, prior detection of P-eIF2-.alpha. by
immunoblot. FIG. 2D Identical experiments performed with
tautomycin, a different PP1 inhibitor.
[0084] FIGS. 3A-3D. PKR phosphorylates eIF2-.alpha. in activated
DCs. FIG. 3A Wild-type and PKR.sup.-/- were stimulated with soluble
poly I:C for different time and PKR and P-eIF2-.alpha. were
detected by immunoblot. Levels of PKR are strongly increased upon
maturation. PKR levels are inversely correlated with the intensity
of P-eIF2-.alpha., which is gradually reduced. In non-activated PKR
DCs levels of P-eIF2-.alpha. are comparable to wild-type DCs, while
upon poly I:C stimulation P-eIF2-.alpha. is nearly abolished. FIG.
3B A comparable decrease of P-eIF2-.alpha. following poly I:C
stimulation (sol) in PKR.sup.-/- DCs was observed upon direct
delivery of poly I:C in the cytosol (lip). A control with sodium
arsenite-treated cells (500 .mu.M, 30') was performed. FIG. 3C
Lipofection of poly I:C (lip) and not soluble poly I:C (sol)
induces PKR-dependent eIF2-.alpha. phosphorylation in wild-type
MEFs and NIH3T3 cells. FIG. 3D NIH3T3 cells were lipofected with
poly I:C for 8 h, with the addition of the proteasome inhibitor
MG132 in the last 4 h of treatment. In contrast to DCs (FIG. 1d)
GADD34 levels are decreased. .beta.-actin immunoblot is shown as an
equal loading control.
[0085] FIGS. 4A-4C. DCs are protected from the inhibition of
translation induced by PKR upon cytosolic poly I:C sensing. FIG. 4A
Monitoring of translation in wild-type and PKR.sup.-/- MEFs, DCs
and NIH3T3 treated with soluble (sol) or lipofected poly I:C (lip)
for 8 h. Lipofection of poly I:C in MEFs (wt) and NIH3T3 induces
PKR-dependent translation arrest. Soluble poly I:C does not affect
NIH3T3 cells, but inhibits translation in wt MEFs. In contrast,
translational arrest by poly I:C treatment is never observed in
DCs. Controls with no puromycin (co), cycloheximide (chx) and
lipofectamine alone (mock) are presented. .beta.-actin immunoblot
is shown for equal loading control. FIG. 4B NIH3T3, MEFs and DCs
were treated for 8 h with lipofected Cy5 labelled-poly I:C prior
monitoring by FACS. One representative experiment of three is
presented. FIG 4C Translation was monitored in DCs stimulated for 4
or 8 h with poly I:C. Protein synthesis was strongly reduced in
presence of salubrinal (added to the cells 2 h before poly I:C
stimulation).
[0086] FIGS. 5A-5C. Signal transduction pathways involved in
eIF2-.alpha. phosphorylation regulation and GADD34 transcription.
FIG. 5A Wild-type, TLR3.sup.-/- and MDA5.sup.-/- DCs were
stimulated with poly I:C for different time prior immunoblotting
for P-eIF2-.alpha., eIF2-.alpha., and PKR. In all cells types, PKR
levels are increased during DC maturation, while eIF2-.alpha. is
dephosphorylated (top panel). In contrast, treatment with the PI3
kinase inhibitor Ly294002 (Ly) (1 h before harvesting) efficiently
prevents eIF2-.alpha.. dephosphorylation (bottom panel). FIG. 5B No
change in eIF2-.alpha.. dephosphorylation is observed in
IFN-.alpha..beta. R.sup.-/- DCs stimulated with poly I:C, while the
levels of PKR are drastically reduced in these cells. FIG. 5C qPCR
monitoring of GADD34 mRNA levels in wild-type and IFN-.alpha..beta.
R.sup.-/- activated DCs. Levels are reduced by to 2 to 6 folds in
the IFN-.alpha..beta. R.sup.-/- compared to wt cells.
[0087] FIGS. 6A-6F. Activated DCs are resistant to stress granules
formation and tryptophan starvation. FIG. 6A DCs were activated
with poly I:C or LPS for different time and treated with 500 .mu.M
sodium arsenite for the last 30' of each time point. Stress
granules (SG) formation was visualised by confocal microscopy after
mRNA in situ hybridization with oligodT and staining with eIF4A
antibody. Bar, 10 .mu.m. (top panel). FIG. 6B The number of DCs
bearing SGs was plotted against the time of maturation. SGs are
found in almost 100% of non-activated DCs, a proportion, which is
reduced upon activation. FIG. 6C Kinetics of SG formation
corresponds to the state of eIF2-.alpha. phosphorylation and GADD34
expression induced by poly I:C or LPS. FIG. 6D Translational
intensity was measured in wild-type and GCN2.sup.-/- MEFs grown in
complete or tryptophan (Trp)-free medium for 6 h. Translation is
inhibited in response to tryptophan depletion in wt but not in
GCN2.sup.-/- MEFs. FIG. 6E DCs, activated with poly I:C for 2 h,
are then starved for 6 h (poly I:C was kept during starvation).
Contrary to MEFs, activated DCs exposed to tryptophan depletion, do
not display any inhibition of translation for at least 6 h.
Controls with no puromycin and cycloheximide (chx) are shown. FIG.
6F .beta.-actin immunoblots are presented as equal loading control.
P-eIF2-.alpha.. and eIF2-.alpha.. were also monitored in wt and
GCN2.sup.-/- MEFs and DCs. eIF2-.alpha. phosphorylation in response
to tryptophan depletion is observed in wt MEFs but not in
GCN.sup.-/- MEFs or DCs (bottom panel).
[0088] FIGS. 7A-7B. eIF2-.alpha. dephosphorylation is essential for
normal IFN-.beta. production and caspase-3 inhibition in DCs. FIG.
7A IFN-.beta. was quantified by ELISA in wild-type and PKR.sup.-/-
bmDCs stimulated with poly I:C for different time. The production
of IFN-.beta. in the PKR.sup.-/- is significantly reduced compared
to wt cells, thus confirming the requirement of PKR for this
process (left panel). IFN-.beta. was quantified in DCs stimulated
with poly I:C or LPS for 8 h, in presence or absence of the
GADD34/PP1 inhibitor salubrinal (added 2 h before stimulation)
(right panel). Upon salubrinal treatment, IFN-.beta. secretion in
activated DCs is drastically reduced, indicating that the control
of eIF2-.alpha. phosphorylation during PKR activation is essential
for normal IFN-.beta. production. FIG. 7B Caspase 3 cleavage was
revealed by immunoblot in DCs stimulated with poly I:C or LPS for 8
h, in presence or absence of salubrinal (added 2 h before
stimulation). Salubrinal treatment alone induces a massive increase
in total levels of caspase-3 (visualised as a band at 35 kDa) and
its cleaved active form (17 kDa). Treatments with poly I:C or LPS
decrease caspase-3 expression and the cleavage induced by
salubrinal alone, probably due to GADD34 induction in activated
DCs. .beta.-actin immunoblot is shown as an equal loading
control.
[0089] FIG. 8. activated DCs deficient for GADD34 are incapable of
producing IFN-.beta. and IL-12.
[0090] Wild-type and GADD34.sup.-/- DCs were stimulated with poly
I:C for different time prior immunoblotting for P-eIF2-.alpha..,
eIF2-.alpha., and PKR. In all cells types, PKR levels are strongly
decreased during DC maturation, while eIF2-.alpha.. is strongly
reduced and phosphorylated (top panel). IFN-.beta. and IL-12 was
quantified by ELISA in wild-type and GADD34.sup.-/- bmDCs
stimulated with poly I:C or LPS for different time. The production
of IFN-.beta. and IL-12 in the GADD34.sup.-/- is significantly
reduced compared to wt cells, thus confirming the requirement of
GADD34 for this process and explaining the poor expression of PKR
in these cells (PKR is IFN inducible).
[0091] FIGS. 9A-9C. GADD34 is required for cytokine (IFN-.beta. and
IL-6) production by poly I:C-stimulated MEFs.
[0092] FIG. 9A After 6 h of poly I:C stimulation, IFN-.beta. (left
panel) and IL-6 (right panel) in cell culture supernatants of
wild-type and GADD34.sup..DELTA.C/.DELTA.C MEFs were quantified by
ELISA. Mock are samples treated with lipofectamine alone. Data are
mean .+-.SD of five (IFN-.beta.) and three (IL-6) independent
experiments. FIG. 9B Wild-type and GADD34.sup..DELTA.C/.DELTA.C
MEFs were treated with poly I:C for the indicated times, total RNA
was extracted and quantitative PCR were performed on cDNA. Fold
increase of the indicated transcripts was calculated compared to a
value=1 for each of the mock samples (treated with lipofectamine
only). IFN-.beta., IL-6 and PKR transcripts were upregulated upon
poly I:C stimulation in both wild-type and
GADD34.sup..DELTA.C/.DELTA.C MEFs and, at late time points, even
more in GADD34.sup..DELTA.C/.DELTA.C MEFs than in wild-type. Level
of Cystatin C transcript remained approximately constant upon poly
I:C treatment in both wild-type and GADD34.sup..DELTA.C/.DELTA.C
MEFs. Data are representative of two independent experiments with
similar results. FIG. 9C Wild-type and GADD34.sup..DELTA.C/.DELTA.C
MEFs were transfected overnight with a plasmid carrying the murine
sequence of GADD34 and then treated with poly I:C for 6 h.
IFN-.beta. production was quantified by ELISA in cell culture
supernatants (left panel), while effective eIF2.alpha.
dephosphorylation was checked by immunoblot (right panel). One of
three independent experiments with similar results is shown.
[0093] FIGS. 10A-10C. CHIKV infection and IFN-.beta. production are
controlled by GADD34 in MEFs.
[0094] FIG. 10A Wild-type and GADD34.sup..DELTA.C/.DELTA.C MEFs
were exposed to 10 or 50 MOI of CHIKV for 24 h or 48 h and
productive infection was estimated by GFP expression. FIG. 10B
IFN-.beta. production by wild-type and GADD34.sup..DELTA.C/.DELTA.C
MEFs exposed to CHIKV was quantified by ELISA in cell culture
supernatants. FIG. 10C Murine IFN-.beta. was added 3 h before
infection of wild-type and GADD34.sup..DELTA.C/.DELTA.C MEFs with
CHIKV (10 MOI). Productive infection was estimated by GFP
expression 24 h after CHIKV exposure. Data represented in A, B and
C mean .+-.SD of triplicates. One of two independent results with
similar results is shown.
[0095] FIG. 11. CHIKV infection in mouse neonates.
[0096] Wild-type (FVB) and GADD34.sup..DELTA.C/.DELTA.C mouse
neonates (12-day-old) were inoculated intradermally with 10.sup.6
PFU of CHIKV and observed for lethality (n=14 per group).
EXAMPLE
[0097] Material & Methods
[0098] Mice
[0099] Male C57BL/6 mice 6 week-old were purchased from Charles
River Laboratories. TLR-3.sup.-/- mice were obtained from L.
Alexopoulou (CIML, Marseille), IFN-.alpha./.beta. R.sup.-/- mice
from M. Dalod (CIML, Marseille), MDA-5.sup.-/- mouse bone marrow
from M. Colonna (Washington University) and PKR.sup.-/- mouse bone
marrow from Caetano Reis e Sousa (Cancer Research UK, London).
[0100] Cell Culture
[0101] Bone marrow-derived DCs were obtained and cultured as
described previously.sup.50. NIH3T3 cells were cultured in RPMI
1640 (GIBCO) supplemented with 10% FCS (HyClone, PERBIO), 100
units/ml penicillin and 100 .mu.g/ml streptomycin (GIBCO).
Wild-type and PKR.sup.-/- MEFs (from Caetano Reis e Sousa) were
cultured in DMEM, 10% FCS, pen/strep. Wild-type and GCN2.sup.-/-
MEFs (from David Ron) were cultured in RPMI, 10% FCS, pen/strep,
MEM non-essential amino acids (GIBCO), 55 .mu.M
beta-mercaptoethanol. For the tryptophan starvation experiments,
MEFs and DCs were cultured for the indicated time in RPMI 1640
Tryptophan--medium (21875, GIBCO). All cells were cultured at
37.degree. C. and 5% CO.sub.2.
[0102] Chemicals
[0103] MEFs, NIH3T3 and immature DCs were treated for the indicated
time with 10 .mu.g/ml poly I:C (InvivoGen), alone or in combination
with lipofectamine 2000 (Invitrogen). 2 .mu.g/ml tunicamycin
(SIGMA) was added to DCs for 2 h; 2 .mu.M MG132 (BIOMOL
International) was added to DCs and NIH3T3 4 h before harvesting;
75 .mu.M salubrinal (Calbiochem) or 100 nM tautomycin (Calbiochem)
were added to DCs 4 h before harvesting; 500 .mu.M sodium arsenite
(SIGMA) was added for 30 min to DCs, NIH3T3 and MEFs ; 50 .mu.M
LY294002 (Calbiochem) was added to DCs 1 h before harvesting.
Immature DCs were treated for the indicated time with 100 ng/ml LPS
(SIGMA).
[0104] Affymetrix Microarray Hybridization and Data Mining
[0105] Total RNA was extracted from bmDCs at different times after
poly I:C stimulation using the RNeasy miniprep kit (Qiagen). For
each condition 100 ng of total RNA were employed to synthesize
double-stranded cDNA using two successive reverse-transcription
reactions according to standard Affymetrix protocols (GeneChip
Two-Cycle Target Labelling, Affymetrix). Linear amplification with
T7-RNA polymerase and biotin labelling were performed by in vitro
transcription by standard Affymetrix procedures. The resulting
biotin-labeled cRNA was fragmented and hybridized to the Affymetrix
Mouse Genome MOE 430 2.0 oligonucleotide 39,000-gene microarray
chip for 16 h at 45.degree. C. Following hybridization, the probe
array was washed and stained on a fluidics station and immediately
scanned on a Affymetrix GCS 3000 GeneArray Scanner. The data
generated from the scan were then analyzed using the MicroArray
Suite software (MAS 5.0, Affymetrix) and normalized using the
GC-RMA algorithm. Bioinformatic analysis was performed using the
GeneSpring GX 9.0 software (Agilent).
[0106] mRNA Quantification by Real-Time RT-PCR
[0107] Total RNA was isolated from DCs using the RNeasy miniprep
kit (Qiagen). cDNA was synthesized from RNA samples using the
Superscript II reverse transcriptase (Invitrogen). Quantitative
real-time PCR was carried out in complete SYBR Green PCR buffer (PE
Biosystem) by using 200 nM of each specific primer. A total of 20
.mu.l of PCR mix was added to 5 .mu.l of cDNA template, and the
amplification was tracked via SYBR Green incorporation by using a
Stratagene sequence detection system. cDNA concentration in each
sample were normalized by using HPRT. A nontemplate control was
also routinely performed. Primers used for gene amplification
(designed with the Primer3 software) have been generated.
[0108] Translation Intensity Measurement
[0109] Puromycin labelling for measuring the intensity of
translation was performed using 10 .mu.g/ml puromycin (SIGMA, min
98% TLC, cell culture tested, P8833, diluted in PBS) was added in
the culture medium and the cells were incubated for 10 min at
37.degree. C. and 5% CO.sub.2. Where indicated, 25 .mu.M
cycloheximide (SIGMA) was added 5 min before puromycin. Cells were
then harvested, centrifugated at 4.degree. C. and washed with cold
PBS prior to cell lysis and immunoblotting with the 12D10
antibody.
[0110] Immunoblotting
[0111] Cells were lysed in 1% Triton X-100, 50 mM Hepes, 10 mM
NaCl, 2.5 mM MgCl.sub.2, 2 mM EDTA, 10% glycerol, 1 mM PMSF,
supplemented with Complete Mini Protease Inhibitor Cocktail Tablets
(Roche). Protein quantification was performed using the BCA Protein
Assay (Pierce). 25-50 .mu.g of Triton X-100-soluble material were
loaded on 2%-12% gradient SDS-PAGE before immunoblotting and
chemiluminescence detection (SuperSignal West Pico Chemiluminescent
Substrate, Pierce). Nuclear extraction was performed using the
Nuclear Complex Co-IP kit (Active Motif). Rabbit polyclonal
antibodies against ATF4 (CREB-2, C-20) and eIF2.alpha. (FL-315)
were from Santa Cruz Biotechnology, as well as mouse monoclonal
against GADD34 (C-19) and PKR (B-10). Rabbit polyclonal antibodies
against P-eIF2.alpha. (Ser 51) and caspase-3 were from BioSource
and Cell Signaling Technology respectively. Mouse monoclonal
antibodies against .beta.-actin and histone H1 were from SIGMA and
Upstate respectively. Secondary antibodies were from Jackson
ImmunoResearch Laboratories. Quantification of eIF2.alpha.
phosphorylation was performed using the Multi Gauge software
(Fujifilm).
[0112] Immunocytochemistry
[0113] DCs were harvested and let adhere on 1% Alcian Blue-treated
coverslips for 10 min at 37.degree. C., fixed with 3%
paraformaldeyde in PBS for 10 min at room temperature,
permeabilized with 0.5% saponin in PBS/5% FCS/100 mM glycine for 15
min at room temperature and stained 1 h with indicated primary
antibody. Goat polyclonal antibody against eIF4A (N-19) was from
Santa Cruz; rat monoclonal antibody against Lamp2 was from I.
Mellman's lab. All Alexa secondary antibodies (30 min staining)
were from Molecular Probes (Invitrogen). Poly I:C was coupled with
Cy5 using the LabelT Cy5 labeling kit (Mirus). Immunofluorescence
and confocal microscopy (using microscope model LSM 510; Carl Zeiss
MicroImaging) were performed using a 63 .times. objective and
accompanying imaging software.
[0114] mRNA In Situ Hybridization
[0115] Stress granules formation was detected by in situ
hybridization with oligo-dT (Alexa Fluor 555 dT18, Invitrogen).
Cells were fixed with PFA, permeabilized with methanol 10 min at
20.degree. C. and incubated with oligodT for 4 h at 43.degree. C.
Next, staining with the primary and secondary antibodies was
performed.
[0116] IFN-.beta. ELISA
[0117] IFN-.beta. quantification in culture supernatant of DCs (5
fold-diluted) was performed using the Mouse Interferon Beta ELISA
kit (PBL InterferonSource) according to manufacturer
instructions.
[0118] Flow Cytometry Analysis
[0119] Cells were stained with specific antibodies for cell surface
markers: CD86-biotin, IA/IE-PE and CD11c-APC (BD Pharmingen) (30
min at 4.degree. C., in PBS/1% FCS). After washing, cells were
stained with PerCP-Cy5.5 streptavidin (BD Pharmingen) (20 min at
4.degree. C., in PBS/1% FCS), then washed and fixed in 2%
paraformaldehyde in PBS. Events were collected on a FACScalibur
(Becton Dickinson) and the data were acquired using the CellQuest
software (BD Biosciences) and analysed using the FlowJo
software.
[0120] Results
[0121] DC Stimulation by poly I:C Induces Part of the ISR Genes
[0122] Protein synthesis is tightly regulated in activated mouse
bone marrow-derived DCs [Lelouard, H. et al., 2007]. To identify
potential molecules involved in this control, we performed
genome-wide expression analysis of poly I:C stimulated DCs using
Affymetrix Mouse Genome 430 2.0 arrays. We found that at least nine
transcripts, typically expressed during the tunicamycin-induced
Unfolded Protein Response (UPR) [Harding, H. P. et al., 2003;
Okada, T., et Al., 2002; Marciniak, S. J. et al., 2004] were
strongly induced. In particular, transcripts coding for the
transcription factors ATF4, ATF3 and CHOP (Ddit3/GADD153) as well
as for MyD116 (GADD34), tryptophanyl-tRNA synthetase (Wars), the
COP2 component Sec23b and the disulfide-bond isomerase Ero11 and
were all upregulated. The upregulation of these transcripts was
confirmed by quantitative RT-PCR (qPCR), demonstrating the
existence of an UPR-related gene expression signature in poly I:C
stimulated DCs.
[0123] ATF4 and CHOP (Ddit3/GADD153) induction is one of the
hallmarks of the UPR [Harding, H. P. et al., 2000]. ATF4 and CHOP
mRNA expression was found by quantitative PCR (qPCR) to be
respectively increased by 2 and 8 folds (FIG. 1a and 1b) in
response to poly I:C. ATF4 mRNA is normally expressed in unstressed
cells but is poorly translated. However, upon stress-mediated
eIF2-.alpha. phosphorylation, a rapid synthesis of the ATF4 protein
can be observed [Harding, H. P. et al., 2000; Scheuner, D. et al.,
2001; Lu, P. D., et Al., 2004]. ATF4 synthesis induces CHOP/GADD153
expression, which in turn triggers the transcription of many
downstream target genes important for the response to a variety of
stress that result in growth arrest or DNA damage (GADD)
[Marciniak, S. J. et al., 2004]. Therefore, we monitored ATF4
levels by immunoblot during DC activation. ATF4 translation was
strongly up-regulated upon poly I:C stimulation and the protein was
mostly detected in the nucleus after 8 h of stimulation.
Interestingly, induction levels were similar to those induced by
tunicamycin (FIG. 1a). Thus, ATF4 expression is induced by poly I:C
detection and drives the transcription of CHOP and its downstream
effectors.
[0124] GADD34 Upregulation in Activated DCs
[0125] One of the main downstream targets of CHOP is GADD34
(MyD116), which serves to relieve translation repression during ER
stress [Marciniak, S. J. et al., 2004; Novoa, I., et Al., 2001;
Novoa, I. et al., 2003]. GADD34 inhibits the catalytic subunit of
protein phosphatase 1 (PP1) that dephosphorylates eIF2-.alpha.. The
expression of PP1 and GADD34 in activated DCs was monitored by qPCR
(FIG. 1c and 1d). PP1 mRNA expression was modestly increased upon
poly I:C exposure. In contrast, GADD34 mRNA transcription was
enhanced at least 14 folds during maturation. GADD34 contains two
PEST sequences promoting rapid proteasome-mediated degradation.
Thus, proteasome inhibition by MG132 was necessary to allow GADD34
detection in cell extracts (FIG. 1d). As expected from the
transcriptional analysis, the protein was found to accumulate
progressively during DC activation, peaking after 8 h of
stimulation and in comparable amounts to the levels induced by
tunicamycin (FIG. 1d). Thus poly I:C stimulation induces in DCs the
transcription and synthesis of several important components of the
UPR including ATF4, CHOP and GADD34. Importantly, GADD34, being a
potent cofactor of PP1, is considered as part of the negative
feedback loop reducing translational stress during the UPR [Novoa,
I., et Al., 2001; Novoa, I. et al., 2003]. In contrast, the
constitutive PP1 cofactor CReP (constitutive repressor of
eIF2-.alpha. phosphorylation [Jousse, C. et al., 2003]) was induced
only very modestly upon DC maturation (FIG. 1e), suggesting no
major role of this molecule during poly I:C detection.
[0126] eIF2-.alpha. is Dephosphorylated During DC Activation
[0127] Protein synthesis in DCs was quantified using puromycin
labelling followed by immunoblot with the anti-puromycin mAb 12D10
(FIG. 2a). As previously demonstrated for LPS-activated DCs,
protein synthesis is enhanced in the first hours of poly I:C
stimulation followed by a reduction after 12-16 h of activation
[Lelouard, H. et al., 2007]. Immunoblot and quantification for
phosphorylated (P-eIF2-.alpha.) and total eIF2-.alpha. were also
performed on the same DC extracts (FIG. 2b). Interestingly
P-eIF2-.alpha. levels were found to be gradually reduced during
poly I:C stimulation.
[0128] The loss of P-eIF2-.alpha. in poly I:C treated cells, which
at this late time of maturation display a reduced protein synthesis
rate, indicates that eIF2-.alpha. phosphorylation is probably not
involved in translation inhibition. However, since eIF2-.alpha.
phosphorylation intensity was inversely correlated with GADD34
expression levels, we tested how targeted inhibition of the
PP1-GADD34 complex activity with the specific inhibitor salubrinal
[Boyce, M. et al., 2005] could affect eIF2-.alpha. in DCs.
Salubrinal alone induced eIF2-.alpha. phosphorylation (FIG. 2c),
which was considerably enhanced in presence of soluble poly I:C.
These results were confirmed using tautomycin, another PP1
inhibitor. Thus, eIF2-.alpha. kinases are functional in DCs and PP1
activity is responsible for the dephosphorylation of eIF2-.alpha.
through the enhanced GADD34 expression triggered by poly I:C
detection.
[0129] PKR is Functional and Phosphorylates eIF2-.alpha. in
Activated DCs.
[0130] PKR functions as a signal transducer in the proinflammatory
response to different microbial products, including LPS and dsRNA.
Alternatively, activation of PKR during infection by viral dsRNA
results in eIF2-.alpha. phosphorylation and inhibition of protein
synthesis. To gain further insights on the role of PKR during DC
activation, wild-type and PKR cells were monitored for eIF2-.alpha.
phosphorylation upon poly I:C stimulation (FIG. 3a). Immature DCs
displayed relatively low levels of PKR, which were strongly
upregulated upon maturation. Interestingly, PKR levels were
inversely correlated with the intensity of eIF2-.alpha.
phosphorylation, which was gradually reduced during maturation. In
non-activated PKR.sup.-/- DCs, levels of P-eIF2-.alpha. were close
to normal, confirming that other kinases than PKR phosphorylate
eIF2-.alpha. in immature DCs (FIG. 3a). However upon poly I:C
exposure, eIF2-.alpha. phosphorylation was nearly abolished in
these cells, confirming that PKR normally mediates eIF2-.alpha.
phosphorylation upon poly I:C detection, but its activity is
counteracted by PP1 activation. This mechanism was also able to
limit eIF2-.alpha. phosphorylation upon direct delivery of poly I:C
in the DC cytosol (FIG. 3b), a mode of targeting which induces
PKR-dependent eIF2-.alpha. phosphorylation in wild-type MEFs and
NIH3T3 cells (FIG. 3c). Although the deletion of PKR impacted the
total levels of P-eIF2-.alpha. in MEFs, poly I:C stimulation did
not influence its phosphorylation compared to control cells,
indicating that the dephosphorylation induced by dsRNA detection in
DCs does not occur in fibroblasts. In agreement with this
observation, GADD34 levels in NIH3T3 cells were found unchanged if
not decreased in response to poly I:C lipofection (FIG. 3d).
[0131] Protein Synthesis is not Inhibited in DCs Exposed to
Cytosolic Poly I:C
[0132] Translation was monitored in DCs and fibroblasts exposed to
soluble or lipofected poly I:C for several hours. Lipofection of
poly I:C in MEFs (wt and PKR.sup.-/-) and NIH3T3 efficiently
induced PKR-dependent translation arrest within 4 to 8 hours (FIG.
4a). Interestingly, although soluble poly I:C did not affect NIH3T3
cells, translation was inhibited in wt MEFs, suggesting that
soluble dsRNA can access efficiently to the cytosol of these cells
and interact with PKR. In the case of DCs, and as anticipated from
the low levels of eIF2-.alpha. phosphorylation induced by poly I:C
lipofection, translation was not inhibited even after 8 hours of
exposure (FIG. 4a). Interestingly, while we verified by FACS that
equivalent amounts of poly I:C were delivered in the cells by
lipofection (FIG. 4b), we visualized poly I:C entry. In addition of
detecting the accumulation of lipofected poly I:C in large
cytosolic aggregates, we could also show that soluble poly I:C
penetrates in the DC cytoplasm and appears as speckles situated
away from LAMP2-positive endo/lysosomes, a phenomenon never
observed in NIH3T3 cells.
[0133] This relatively efficient access of soluble poly I:C to DC
cytosol suggests that PKR could be activated concomitantly with
TLR3 and MDA5. This hypothesis is supported by the observation that
soluble poly I:C strongly accentuates eIF2-.alpha. phosphorylation
in presence of salubrinal, which inhibits specifically the
PP1/GADD34 activity (FIG. 2c). Moreover, protein synthesis in poly
I:C stimulated DCs was strongly reduced in presence of salubrinal
(FIG. 4c), suggesting that activated DCs rely on the induction of
PP1/GADD34 activity to resist PKR-dependent translational arrest by
shifting the biochemical equilibrium toward eIF2-.alpha.
dephosphorylation.
[0134] Signal Transduction Pathways Involved in GADD34
Transcription Upregulation
[0135] We used DCs generated from mice lacking the dsRNA sensors
TLR3 and MDA5 to determine the signaling cascade responsible for
the triggering of eIF2-.alpha. dephosphorylation (FIG. 5). DCs were
stimulated with poly I:C as indicated prior immunobloting for
P-eIF2-.alpha. (FIG. 5a). Single inactivation of TLR3 or MDA5 did
not affect eIF2-.alpha. phosphorylation compared to control cells.
Thus, the cascade inducing GADD34 expression can be probably
triggered by the stimulation of any of these receptors, which is
likely to occur in the endosomes or via the passage of poly I:C in
the cytosol. Recently, we have shown that PI3 kinase activation is
necessary to achieve full DC maturation in response to TLR ligation
and that is involved in controlling translation upregulation
[Lelouard, H. et al., 2007]. We therefore monitored eIF2-.alpha.
phosphorylation in presence of the PI3K inhibitor LY294002 (LY)
(FIG. 5a). LY treatment efficiently prevented eIF2-.alpha.
dephosphorylation, indicating that PI3K signaling and the induction
of the stress response pathway in activated DCs are tightly linked.
The relatively late stage of maturation at which eIF2-.alpha. is
dephosphorylated led us to investigate whether the autocrine
activity of IFN-.beta. could be involved in this process. Although
IFN receptor signaling is required to achieve normal DC maturation
and abundant IFN-.beta. production (FIG. S3), no change in
eIF2-.alpha. phosphorylation was observed in poly I:C-activated
IFN-.alpha..beta. receptor (IFN-.alpha..beta. R.sup.-/-) DCs (FIG.
5b). In contrast, qPCR quantification indicated that GADD34 mRNA
levels were reduced by two to six folds compared to wt cells (FIG.
5c). Interestingly, IFN-.beta. receptor signalling was also shown
to be responsible for the strong upregulation of PKR during DC
maturation (FIG. 5b). This lack of PKR upregulation could therefore
compensate for the relative loss of GADD34 activity in stimulated
IFN-.alpha..beta.R.sup.-/- DCs, explaining why the rate of
eIF2-.alpha. dephosphorylation remains unchanged or is even higher
at late time points. Thus, the autocrine effect of IFN-.beta. on
DCs contributes significantly to GADD34 induction.
[0136] Activated DCs Resist to Stress Inducing Translation
Inhibition
[0137] As seen with poly I:C, eIF2-.alpha. dephosphorylation is
likely to increase DC resistance to other stress causing
translational arrest. Arsenite treatment induces the formation of
stress granules (SG), which serves as depository of mRNA and
translational factors and require eIF2-.alpha.phosphorylation for
their formation [Kedersha, N. & Anderson, P., 2002; Anderson,
P. & Kedersha, N, 2002; Kedersha, N. et al., 2005]. SG
induction by arsenite was visualised by confocal microscopy
detection of poly-A mRNA and eIF4a during DC stimulation by poly
I:C or LPS (FIG. 6a). SGs were found in almost 100% of
non-activated DCs, a proportion which was progressively reduced to
15% upon activation. Interestingly, the intensity and kinetics of
SG formation mirrored perfectly the state of eIF2-.alpha.
phosphorylation and GADD34 expression induced by poly I:C or LPS
(FIG. 6a). Surprisingly, the kinetics of eIF2-.alpha.
dephosphorylation in LPS stimulated DCs were strikingly different
from those induced by poly I:C.
[0138] Amino acids starvation is also known to induce eIF2-.alpha.
phosphorylation. Interestingly, tryptophan depletion mediated by
the enzyme indoleamine 2,3-dioxygenase (IDO), which is produced in
activated DCs, promotes peripheral tolerance by causing T cell
anergy [Mellor, A. L. & Munn, D. H., 2004; Puccetti, P., 2007].
The GCN2 kinase in T cells is partially responsible for this
phenomenon by sensing deacylated tryptophan-tRNAs and causing
eIF2-.alpha. phosphorylation [Munn, D. H. et al., 2005]. We tested
whether DC activation would also prevent translation arrest upon
tryptophan starvation. Translation inhibition and eIF2-.alpha.
phosphosphorylation in response to tryptophan depletion were
clearly observed in wt MEFs grown in tryptophan-free media for 6
hours but not in GCN2.sup.-/- MEFs (FIG. 6b). In MEFs, translation
inhibition was already detectable after 2 h of starvation and total
after 8 h, concomitantly with an enhancement in eIF2-.alpha.
phosphorylation. Based on these observations, DCs were activated
during 2 h with poly I:C prior tryptophan starvation (keeping poly
I:C during starvation). Contrary to MEFs, activated DCs, submitted
to tryptophan depletion, did not exhibit any translation inhibition
over 6 hours, presumably due to induction of GADD34 and its
subsequent control of eIF2-.alpha. phosphorylation (FIG. 6b). The
inducible expression in DCs of tryptophanyl-tRNA synthetase (Wars)
at these times could also favor protein synthesis in tryptophan
starvation conditions and accentuate the phenotype. Unfortunately,
we could not monitor translation activity in non-stimulated DCs,
since the experimental starvation conditions, used here, induced
their spontaneous maturation and/or cell death. Thus, activated
[0139] DCs specifically display an acute resistance to most of the
stress inducing eIF2-.alpha. phosphorylation and inhibiting
cap-mediated translation.
[0140] eIF2-.alpha. Phosphorylation and DC Function
[0141] PKR has been shown to be an important mediator of cytokine
production and apoptosis through eIF2-.alpha. phosphorylation and
p38 pathway activation, notably upon LPS detection by macrophages
[Hsu, L. C. et al., 2004]. We therefore evaluated the impact of
eIF2-.alpha. phosphorylation on IFN-.beta. expression, the major
cytokine produced by DCs upon poly I:C stimulation [Diebold, S. S.
et al., 2007] (FIG. 7a). PKR DCs stimulated with poly I:C displayed
extremely reduced levels of IFN-.beta. secretion compared to wt
cells, thus confirming the requirement of PKR activation for this
process [Samuel, C. E., 2001]. We next tested the impact of
GADD34/PP1 inhibition on IFN-.beta. secretion by DCs. Upon
salubrinal treatment, IFN-.beta. secretion was drastically reduced
in poly I:C treated DCs, indicating that uncontrolled eIF2-.alpha.
phosphorylation during PKR activation could impair normal
IFN-.beta. production. Thus GADD34 expression is required to
compensate for concomitant PKR activation and achieve functional
maturation during DC activation.
[0142] We further tested if deregulated eIF2-.alpha.
phosphorylation could also lead to apoptosis in activated DCs
[Scheuner, D. et al., 2006; Rintahaka, J., et Al., 2008]. DCs were
exposed to various stimuli and pharmacological treatments prior
caspase-3 detection by immunoblotting (FIG. 7b). Although addition
of poly I:C or LPS had little effect, salubrinal treatment alone
induced a massive increase in total levels of caspase-3 and in its
cleaved active product, generally seen as an important step for
apoptosis initiation. Thus, eIF2-.alpha. phosphorylation seems to
have a direct effect on the synthesis and the cleavage of
caspase-3. Treatments with both salubrinal and poly I:C or LPS had
a lighter effect than salubrinal alone, probably due to GADD34
induction in activated DCs which renders them more resistant to
salubrinal induced inhibition. These experiments confirm the need
of controlling eIF2-.alpha. phophorylation to avoid abnormal
induction of caspase-3, a situation, which would normally be
prevented by GADD34 expression and eIF2-.alpha. dephophorylation in
activated DCs.
GADD34 Expression is Necessary to Produce Cytokines in Fibroblasts
in Response to dsRNA [0143] Cytosolic poly I:C detection in mouse
embryonic fibroblasts (MEFs) also promotes a PKR-dependent mRNA
translation arrest and an ISR-like response, during which, ATF4 and
its downstream target the phosphatase-1 (PP1) cofactor, growth
arrest and DNA damage-inducible protein 34 (GADD34/MyD116/Ppp1r15a)
are strongly up-regulated. Interestingly, although most of mRNA
translation is strongly inhibited by poly I:C, IFN-beta
(IFN-.beta.), Interleukin-6 (IL-6) and PKR synthesis are all
considerably increased in these conditions. We further demonstrate
that PKR-dependent expression of GADD34 is absolutely required for
the normal translation of IFN-.beta. and IL-6 mRNAs, while
dispensable for PKR neo-synthesis (FIG. 9). We have recapitulated
these observations using CHIKV as a pathological-relevant model and
show that GADD34-deficient MEFs are extremely permissive to the
virus due to their inability to produce type-I interferon (FIG.
10). We further show that, although normal 12 days old mice are
fully resistant to CHIKV infection, GADD34-deficiency induces 100%
of mortality among the neonates of the same age (FIG. 11). Our
observations demonstrate that induction of the ATF4 transcription
program is part of the anti-viral response and imply the existence
of several distinct and segregated group of mRNA translated
differently during dsRNA-induced eIF2-.alpha. phosphorylation.
[0144] Discussion
[0145] Translation inhibition occurs in response to many stress in
which cellular activity has to be orientated or suspended
momentarily. We demonstrate here that the cellular defense pathways
involving the different PKR-like kinases and eIF2-.alpha.
phosphorylation are inactivated in activated DCs. We have shown
that poly I:C treated cells display a gene expression signature
sharing common features with an integrated stress response,
including CHOP and GADD34 induction. Interestingly GADD34 induction
was also recently singled out in a transcriptome analysis of
Lysteria monocytogenes-infected macrophages [Leber, J. H. et al.,
2008], suggesting that its expression is associated with pathogen
detection in different APCs. GADD34 associates with the catalytic
subunit of PP1, which dephosphorylates eIF2-.alpha. and counteracts
PKR-like kinases activity.
[0146] During our investigations, we could not identify a unique
signaling pathway responsible for GADD34 induction. GADD34
expression has been primarily shown to operate as a negative
feedback loop during unfolded protein responses (UPR). DCs have
also been reported to express unusually high levels of XBP-1, a
transcription factor essential for ER homeostasis during UPR [Ron,
D. & Walter, P., 2007; Yoshida, H., et Al., 2001; Calfon, M. et
al., 2002], which is necessary for normal DC survival and function
including IFN-.beta. expression [Iwakoshi, N. N., et Al., 2007;
Smith, J. A. et al., 2008]. Moreover, we have shown that DC
activation leads to a massive increase in protein translation as
well as the production of numerous cytokines, which are mostly
using the ER-mediated secretion pathway. Interestingly, LPS and
poly I:C induce differently GADD34, while also triggering different
levels and kinetics of cytokines production. Moreover, GADD34
expression is decreased in activated IFN-.alpha..beta. R.sup.-/-
DCs, which produce reduced levels of cytokines in response to
microbial products. Finally, eIF2-.alpha. dephosphorylation is
prevented by the PI3K pharmacological inhibitor LY294002, which has
also a strong inhibitory effect on protein synthesis [Lelouard, H.
et al., 2007]. GADD34 expression is therefore tightly linked to the
intensity of protein synthesis and cytokine production in activated
DCs. It is possible that the burst of protein synthesis early
during DC maturation could promote a transient UPR-like situation
leading to ATF4 translation and subsequent GADD34 expression.
Interestingly, although eIF2-.alpha. is clearly phosphorylated in
immature DCs, no major increase in this phosphorylation was
observed during the first phase of activation to fully explain ATF4
translation. Thus, the transcriptional response to poly I:C
detection is relatively different from what is normally observed
during previously characterized UPRs and potentially involves a
novel signaling mechanism capable of inducing ATF4 production.
[0147] We have shown that soluble dsRNA access rapidly the cytosol
of DCs and has therefore the potential to interact with both MDA5
and PKR. PKR is rapidly activated by TLR ligands to promote p38 and
NF-.kappa.B signaling [Williams, B. R., 2001]. PKR activation is
therefore necessary to achieve functional DC maturation, however
its activation should also normally lead to translation inhibition
through eIF2-.alpha. phosphorylation. The existence of the
ATF4/GADD34 response could therefore be adapted to the microbial
stimuli detected and the levels of PKR activation required to
achieve functional DC maturation. Poly I:C is probably an extreme
example since it can induce PKR through TLR signaling and also
through direct recognition. This negative control loop would be
particularly important to avoid premature apoptosis and to ensure
optimal cytokine production.
[0148] GADD34 induction could also have some additional protective
effect against some aspects of DC maturation itself. Indeed,
indoleamine 2,3-dioxygenase (IDO) and heme-oxygenase-I (HO-1) are
two catabolic enzymes produced by tumors and mature DCs, which
shape the immune response by depleting respectively tryptophan and
porphyrin in the DC vicinity [Munn, D. H. et al., 2005; Uyttenhove,
C. et al., 2003; Chauveau, C. et al., 2005; Munn, D. H., 2006].
Neighboring T cells exposed to these conditions are anergized or
differentiated through the activation of GCN2 (tryptophan
depletion) or HRI (heme depletion). GADD34 expression could
therefore protect DCs from the detrimental effects of tryptophan
starvation and also probably of heme depletion triggered by their
own activation or the activation of neighboring DCs. This
specificity allows DCs to prioritize the signaling transduction
pathways governing their innate immunity function over the pathways
normally protecting their cellular integrity from stress which, if
activated, would lead to translational arrest, apoptosis or anergy
in most cells types [Freigang, S., et Al., 2005].
EXAMPLE 2
GADD34 is Necessary to Control Chikungunya virus Infection and IFN
Production In Vitro and In Vivo
[0149] Material & Methods
[0150] Virus.
[0151] CHIKV isolates were obtained from individuals during the
2005-06 CHIKV outbreak in La Reunion Island and amplified on
mosquito C6/36 cell as described [4]. CHIKV-21 was isolated from
the serum of a newborn male with CHIKV-associated encephalopathy;
CHIKV-27 was isolated from the CSF of another new-born male with
encephalopathy; CHIKV-115 from the serum of a 24-year old female
with classical CHIK symptoms. CHIKV-117 was isolated at the
Institut de Medecine Tropicale du Service de Sante des Armees
(IMTSSA), Marseille, France during the 2000 CHIKV outbreak in
Democratic Republic of the Congo from the serum of a person
presenting classical CHIK symptoms. Titers of virus stocks were
determined by standard Vero cell plaque assay and are expressed as
PFU per ml.
[0152] Cells.
[0153] Control and GADD34-/- mouse embryonic fibroblastswere
infected with CHIKV at a multiplicity of infection (MOI) of 10 and
50.
[0154] Animals.
[0155] Inbred FVB mice were obtained from Charles River
laboratories (France). Mice were bred according to the Institut
Pasteur guidelines for animal husbandries and were kept in level-3
isolators. Mice were inoculated by ID in the ventral thorax with 50
.mu.l of a viral suspension diluted with PBS for adult mice and
with 30 .mu.l for neonates. Mock-infected mice received PBS alone.
Mice were anesthetized with isoflurane (Forene, Abbott Laboratories
Ltd, United-Kingdom). Blood was collected by cardiac puncture after
which each mouse was perfused via the intracardiac route with 40 ml
of PBS at 4.degree. C. before harvesting of organs. Tissues were
homogenized, and virus titers of each tissue sample determined on
Vero cells by tissue cytopathic infectious dose 50 (TCID50), and
viral titers in tissues and in serum were expressed as TCID50/g or
TCID50/ml, respectively. The principles of good laboratory animal
care were followed all through the experimental process. Mortality
studies were performed on groups of six mice and viral titers in
tissues from four mice at each time point.
[0156] Histology and Immunofluorescence.
[0157] Mouse organs were snap frozen in isopentane cooled by liquid
nitrogen for cryosectionning or fixed in para-formaldehyde for
paraffin embedding. Paraffin-embedded tissues were processed for
histological staining (Hematoxylin and eosin). For
immunofluorescence, cryosections were fixed for 10 min in ice-cold
methanol before incubation for 12 h at 4.degree. C. with the
primary antibodies followed by incubation for 1 h with the
secondary antibodies. Slides were counterstaining with Hoechst
(Vector Lab). The following antibodies were used: polyclonal rabbit
anti-collagen IV (Chemicon, Temecula Calif., 1:200), polyclonal
chicken anti-vimentin (Abcam, Cambridge, UK, 1:200), monoclonal
mouse anti-GFAP (BD pharmingen 1:1,000 or 1:5,000 to only see the
glia limitans), monoclonal rat anti-macrophage antigen F4/80
(Abcam, 1:100), polyclonal rabbit anti-PECAM1/CD31 (Abcam, 1:400),
human serum anti-CHIKV were obtained and characterized by the
Centre National de Reference des Arbovirus as positive for
anti-CHIKV IgM and IgG. The marker specificities were
systematically confirmed by examining sections in which the primary
antibody was replaced by control isotype or immunoglobulins at the
same concentration and by immunostaining of non-infected tissues
from the same animal strain. Slides were examined with a Zeiss
AxioPlan 2 microscope equipped with an ApoTome system in order to
obtain 0.7 .mu.m thick optical sections. Pictures and Z-stacks were
obtained using the AxioVision 4.5 software. When necessary, images
were processed using the image J software
(http://rsb.info.nih.gov.gate2.inist.fr/ij/).
[0158] Results
[0159] Fibroblast of both human and mouse origin constitutes a
major target cell of CHIKV at the acute phase of the infection. In
adult mouse with a totally abrogated type-I IFN signaling,
[0160] CHIKV-associated disease is particularly severe and
correlates with higher viral loads. Importantly, mice with one copy
of the IFN-.alpha./.beta. receptor (IFNAR) gene develop a mild
disease, strengthening the implication of type-I IFN signaling in
the control of CHIKV replication. CHIKV is therefore a particularly
relevant pathogen to confirm our observations on the role of PKR
and GADD34 in controlling type-I IFN production in response to
dsRNA. Mouse wt and GADD34.DELTA.C/.DELTA.C MEFs were exposed to
106 PFU CHIKV (range 0.1-50 multiplicity of infection [MOI]) for 24
or 48 h. Culture supernatants were monitored for the presence of
type I IFNs, while productive infection was estimated by GFP
expression (FIG. 10 A and B). Productive CHIKV infection could only
be observed at maximum MOI in wt MEFs, while IFN-.beta. was
detected at low MOI and robust amount were produced at a higher
range of infection. Contrasting with these results, a very high
level of viral replication was observed in GADD34.DELTA.C/.DELTA.C
MEFs, which were exquisitely sensitive to CHIKV displaying a 50%
infection rate compared to the mere 15% observed in wt MEFS after
24 h of infection (MOI 50). Correlated with this hypersensitivity,
IFN-.beta. production could not be detected during CHIKV infection
of GADD34.DELTA.C/.DELTA.C MEFs, indicating again their incapacity
to produce cytokines in response to cytosolic dsRNA, which is
likely to facilitate viral replication in the culture. This
interpretation is clearly supported by the similar abrogation of
viral replication in both WT and GADD34.DELTA.C/.DELTA.C MEFs
briefly treated with IFN-.beta. prior infection (FIG. 10C),
demonstrating that GADD34 inactivation does not favor viral
replication in presence of sufficient IFN levels.
[0161] Like in Humans, CHIKV pathogenicity is strongly
age-dependent in mice, and in less than 12 day-old mouse neonates,
CHIKV induces a severe disease accompanied with a high rate of
mortality [Couderc, 2008]. Several components of the innate immune
response have been shown to impact on the resistance of older mice
and to restrict efficiently CHIKV infection and its consequences.
Intra-dermal (ID) injections of 106 PFU of CHIKV were performed in
wt (FVB) and GADD34.DELTA.C/.DELTA.C neonates mice to determine the
importance of the GADD34 pathway during the establishment of the
innate anti-viral response in whole animals. As previously observed
for C57/BL6 mice [Couderc, 2008], when CHIKV inoculation was
performed on 12 days old FVB neonates, a 100% survival rate was
observed among the pups (FIG. 11). Strongly contrasting with these
results, 12 days old GADD34.DELTA.C/.DELTA.C neonates all died
within 72 h of CHIKV infection (FIG. 11). Further demonstrating
that functional GADD34 expression is a key component of the
anti-viral pathway and is forming with ATF4 and PKR a signaling
module specialized in the type-I IFN response to specific viruses
including the alphavirus group and probably several other viral
families which are detected by MDA5 and PKR.
[0162] These results show that inhibiting the formation of the
PP1/GADD34 complex by using an inhibitor as defined above may be
useful for decreasing the capacity of cells to produce cytokine.
Inhibitors according to the invention may thus be used to treat
inflammatory conditions such as sepsis or exacerbated inflammatory
conditions caused by an infectious or viral disease.
REFERENCES
[0163] Throughout this application, various references describe the
state of the art to which this invention pertains. The disclosures
of these references are hereby incorporated by reference into the
present disclosure.
[0164] Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell,
R. A. Recognition of double-stranded RNA and activation of
NF-kappaB by Toll-like receptor 3. Nature 413, 732-8 (2001).
[0165] Anderson, P. & Kedersha, N. Stressful initiations. J
Cell Sci 115, 3227-34 (2002).
[0166] Berlanga, J. J. et al. Antiviral effect of the mammalian
translation initiation factor 2alpha kinase GCN2 against RNA
viruses. Embo J 25, 1730-40 (2006).
[0167] Boyce, M. et al. A selective inhibitor of elF2alpha
dephosphorylation protects cells from ER stress. Science 307, 935-9
(2005).
[0168] Calfon, M. et al. IRE1 couples endoplasmic reticulum load to
secretory capacity by processing the XBP-1 mRNA. Nature 415, 92-6
(2002).
[0169] Chauveau, C. et al. Heme oxygenase-1 expression inhibits
dendritic cell maturation and proinflammatory function but
conserves IL-10 expression. Blood 106, 1694-702 (2005).
[0170] Chen, J. J. & London, I. M. Regulation of protein
synthesis by heme-regulated eIF-2 alpha kinase. Trends Biochem Sci
20, 105-8 (1995).
[0171] Connor, J. H., Weiser, D. C., Li, S., Hallenbeck, J. M.
& Shenolikar, S. Growth arrest and DNA damage-inducible protein
GADD34 assembles a novel signaling complex containing protein
phosphatase 1 and inhibitor 1. Mol Cell Biol 21, 6841-50
(2001).
[0172] Couderc T, Chretien F, Schilte C, Disson O, Brigitte M,
Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I,
Despres P, Arenzana-Seisdedos F, Michault A, Albert M L, Lecuit M.
A mouse model for Chikungunya: young age and inefficient type-I
interferon signaling are risk factors for severe disease. PLoS
Pathog. 2008 Feb 8;4(2):e29.
[0173] Diebold, S. S. et al. Viral infection switches
non-plasmacytoid dendritic cells into high interferon producers.
Nature 424, 324-8 (2003).
[0174] Donze, O. et al. The protein kinase PKR: a molecular clock
that sequentially activates survival and death programs. Embo J 23,
564-71 (2004).
[0175] Freigang, S., Probst, H. C. & van den Broek, M. DC
infection promotes antiviral CTL priming: the `Winkelried`
strategy. Trends Immunol 26, 13-8 (2005). Munn, D. H. Indoleamine
2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Curr Opin Immunol 18, 220-5 (2006).
[0176] Gitlin, L. et al. Essential role of mda-5 in type I IFN
responses to polyriboinosinic:polyribocytidylic acid and
encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 103,
8459-64 (2006).
[0177] Harding, H. P., Zhang, Y., Bertolotti, A., Zeng, H. &
Ron, D. Perk is essential for translational regulation and cell
survival during the unfolded protein response. Mol Cell 5, 897-904
(2000).
[0178] Harding, H. P. et al. Regulated translation initiation
controls stress-induced gene expression in mammalian cells. Mol
Cell 6, 1099-108 (2000).
[0179] Harding, H. P. et al. An integrated stress response
regulates amino acid metabolism and resistance to oxidative stress.
Mol Cell 11, 619-33 (2003).
[0180] Hsu, L. C. et al. The protein kinase PKR is required for
macrophage apoptosis after activation of Toll-like receptor 4.
Nature 428, 341-5 (2004).
[0181] Iwakoshi, N. N., Pypaert, M. & Glimcher, L. H. The
transcription factor XBP-1 is essential for the development and
survival of dendritic cells. J Exp Med 204, 2267-75 (2007).
[0182] Jousse, C. et al. Inhibition of a constitutive translation
initiation factor 2alpha phosphatase, CReP, promotes survival of
stressed cells. J Cell Biol 163, 767-75 (2003).
[0183] Kawai, T. & Akira, S. Innate immune recognition of viral
infection. Nat Immunol 7, 131-7 (2006).
[0184] Kedersha, N. & Anderson, P. Stress granules: sites of
mRNA triage that regulate mRNA stability and translatability.
Biochem Soc Trans 30, 963-9 (2002).
[0185] Kedersha, N. et al. Stress granules and processing bodies
are dynamically linked sites of mRNP remodeling. J Cell Biol 169,
871-84 (2005).
[0186] Leber, J. H. et al. Distinct TLR- and NLR-mediated
transcriptional responses to an intracellular pathogen. PLoS Pathog
4, e6 (2008).
[0187] Lelouard, H. et al. Regulation of translation is required
for dendritic cell function and survival during activation. J Cell
Biol 179, 1427-39 (2007).
[0188] Lu, L., Han, A. P. & Chen, J. J. Translation initiation
control by heme-regulated eukaryotic initiation factor 2alpha
kinase in erythroid cells under cytoplasmic stresses. Mol
[0189] Cell Biol 21, 7971-80 (2001).
[0190] Lu, P. D., Harding, H. P. & Ron, D. Translation
reinitiation at alternative open reading frames regulates gene
expression in an integrated stress response. J Cell Biol 167, 27-33
(2004).
[0191] Marciniak, S. J. et al. CHOP induces death by promoting
protein synthesis and oxidation in the stressed endoplasmic
reticulum. Genes Dev 18, 3066-77 (2004).
[0192] Mellman, I. & Steinman, R. M. Dendritic cells:
specialized and regulated antigen processing machines. Cell 106,
255-8 (2001).
[0193] Mellor, A. L. & Munn, D. H. IDO expression by dendritic
cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4,
762-74 (2004).
[0194] Munn, D. H. et al. GCN2 kinase in T cells mediates
proliferative arrest and anergy induction in response to
indoleamine 2,3-dioxygenase. Immunity 22, 633-42 (2005).
[0195] Novoa, I., Zeng, H., Harding, H. P. & Ron, D. Feedback
inhibition of the unfolded protein response by GADD34-mediated
dephosphorylation of eIF2alpha. J Cell Biol 153, 1011-22
(2001).
[0196] Novoa, I. et al. Stress-induced gene expression requires
programmed recovery from translational repression. Embo J 22,
1180-7 (2003).
[0197] Okada, T., Yoshida, H., Akazawa, R., Negishi, M. & Mori,
K. Distinct roles of activating transcription factor 6 (ATF6) and
double-stranded RNA-activated protein kinase-like endoplasmic
reticulum kinase (PERK) in transcription during the mammalian
unfolded protein response. Biochem J 366, 585-94 (2002).
[0198] Proud, C. G. PKR: a new name and new roles. Trends Biochem
Sci 20, 241-6 (1995).
[0199] Puccetti, P. On watching the watchers: IDO and type I/II
IFN. Eur J Immunol 37, 876-9 (2007).
[0200] Rintahaka, J., Wiik, D., Kovanen, P. E., Alenius, H. &
Matikainen, S. Cytosolic antiviral RNA recognition pathway
activates caspases 1 and 3. J Immunol 180, 1749-57 (2008).
[0201] Ron, D. & Walter, P. Signal integration in the
endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell
Biol 8, 519-29 (2007).
[0202] Samuel, C. E. Antiviral actions of interferons. Clin
Microbiol Rev 14, 778-809, table of contents (2001).
[0203] Scheuner, D. et al. Translational control is required for
the unfolded protein response and in vivo glucose homeostasis. Mol
Cell 7, 1165-76 (2001).
[0204] Scheuner, D. et al. Double-stranded RNA-dependent protein
kinase phosphorylation of the alpha-subunit of eukaryotic
translation initiation factor 2 mediates apoptosis. J Biol Chem
281, 21458-68 (2006).
[0205] Smith, J. A. et al. Endoplasmic reticulum stress and the
unfolded protein response are linked to synergistic IFN-beta
induction via X-box binding protein 1. Eur J Immunol 38, 1194-203
(2008).
[0206] Todd, D. J., Lee, A. H. & Glimcher, L. H. The
endoplasmic reticulum stress response in immunity and autoimmunity.
Nat Rev Immunol 8, 663-674 (2008).
[0207] Uyttenhove, C. et al. Evidence for a tumoral immune
resistance mechanism based on tryptophan degradation by indoleamine
2,3-dioxygenase. Nat Med 9, 1269-74 (2003).
[0208] Williams, B. R. PKR; a sentinel kinase for cellular stress.
Oncogene 18, 6112-20 (1999).
[0209] Williams, B. R. Signal integration via PKR. Sci STKE 2001,
RE2 (2001).
[0210] Yoshida, H., Matsui, T., Yamamoto, A., Okada, T. & Mori,
K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to
ER stress to produce a highly active transcription factor. Cell
107, 881-91 (2001).
[0211] Zhang, P. et al. The GCN2 elF2alpha kinase is required for
adaptation to amino acid deprivation in mice. Mol Cell Biol 22,
6681-8 (2002).
[0212] Zhang, K. & Kaufman, R. J. From endoplasmic-reticulum
stress to the inflammatory response. Nature 454, 455-62 (2008).
* * * * *
References